Does Rallies show ACAD 10-K and 10-Q filings?

Rallies organizes ACAD SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.

Is ACAD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.

ACAD (Acadia Pharmaceuticals Inc.) Stock Analysis - SEC Filings

Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find ACAD SEC filings?

Rallies organizes ACAD SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

ACAD Key Metrics

Key financial metrics for ACAD
Metric	Value
Price	$20.95
Market Cap	$3.54B
P/E Ratio	9.34
EPS	$2.23
Dividend Yield	0.00%
52-Week High	$28.35
52-Week Low	$13.40
Volume	0
Avg Volume	0
Revenue (TTM)	$1.10B
Net Income	$375.65M
Gross Margin	91.47%

Latest ACAD News

Acadia Q1 EPS $0.02, $268.1M Revenue Miss, $1.22B–$1.28B Outlook — May 6, 2026
Acadia Pharmaceuticals Upgraded to Buy After 25% Pullback, Maintains $29 Target — Mar 25, 2026
EU Rejects Trofinetide for Rett Syndrome, Acadia Plans Re-Examination — Mar 5, 2026
ACADIA Q4 Sales Surge to $284M, Guides $1.22–1.28B 2026 Revenue, Wolfe Sets $33 Target — Mar 2, 2026
Acadia Posts Record Q4 Revenue Growth, Announces Phase III Pipeline Starts — Feb 26, 2026

Recent ACAD Insider Trades

Kihara James sold 1.33K (~$29.02K) on May 4, 2026.
Schneyer Mark C. sold 3.51K (~$76.40K) on May 4, 2026.
Schneyer Mark C. sold 2.71K (~$60.14K) on Apr 7, 2026.

ACAD Analyst Consensus

15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.77.

Common questions about ACAD

Where can I find ACAD SEC filings?: Rallies organizes ACAD SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show ACAD 10-K and 10-Q filings?: Rallies organizes ACAD SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is ACAD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.